CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma.

TLDR: The trend for OS and ORR benefit with nivolumab for multiple subgroups, without notable safety concerns, may help to guide treatment decisions, and further supports nivorumab as a new standard of care across a broad range of patients with previously treated aRCC.

About: This article is published in European Urology.The article was published on 2017-12-01 and is currently open access. It has received 199 citations till now. The article focuses on the topics: Nivolumab & Everolimus.

Figures

Fig. 3 – Kaplan-Meier curves for overall survival by (A) prior sunitinib therapy, (B) prior pazopanib therapy, and (C) prior interleukin-2 therapy. CI = confidence interval; HR = hazard ratio; NR = not reached; OS = overall survival.

Fig. 4 – Overall survival by first-line therapy duration of (A) <6 mo and (B) I6 OS = overall survival.

Table 1 – Distribution of randomized patients within each subgroup

Table 2 – Summary of treatment-related adverse events for patients within each subgroup

Fig. 2 – Kaplan-Meier curves for overall survival by (A) favorable, (B) intermediate, and (C) poor MSKCC risk group. CI = confidence interval; HR = hazard ratio; MSKCC = Memorial Sloan Kettering Cancer Center; NR = not reached; OS = overall survival.

Fig. 1 – Forest plots of (A) overall survival and (B) objective response rate by baseline characteristics (risk group, age group, number and sites of metastases, prior therapy). CI = confidence interval; IL-2 = interleukin-2; IMDC = International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC = Memorial Sloan Kettering Cancer Center; ORR = overall response rate; OS = overall survival.

Frequently asked questions

Q1. What are the contributions mentioned in the paper "Checkmate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma" ?

Roussy et al. this paper investigated the effect of demographic and pre-treatment factors, including prior therapy, with an impact on outcomes with nivolumab versus everolimus. 

Q2. What have the authors stated for future works in "Checkmate 025 randomized phase 3 study: outcomes by key baseline factors and prior therapy for nivolumab versus everolimus in advanced renal cell carcinoma" ?

Further research should focus on the development of predictive models of outcomes more aligned with immunotherapy in accordance with findings from this study. These results further support the use of nivolumab as a new standard of care [ 21,23,24 ] for a broad range of patients with previously treated aRCC.